DGAP-Adhoc

4SC Signs Licensing and Development Agreement with Menarini for Resminostat in Asia-Pacific Excluding Japan - Seite 4

Resminostat is partnered with Yakult Honsha for Japan and with Menarini in
China and the Asia Pacific (APAC) region excluding Japan.

About Menarini Asia-Pacific

Menarini Asia-Pacific is part of the world's largest Italian
biopharmaceutical company with a heritage of over 129 years and over 16,000
employees in more than 100 countries. Menarini Asia-Pacific's vision is to
be a leading provider of important healthcare brands to improve the lives
of people in the region. Menarini Asia-Pacific operates across the entire
commercial value chain, from clinical development, regulatory approval and
product launch to lifecycle management with a diverse portfolio of
proprietary and partnered brands in key therapeutic fields, including
Consumer Health, Dermatology, Primary Care, Allergy/Respiratory,
Cardiovascular, Oncology/Specialty Care and Men's Health.

About 4SC

The Group managed by 4SC AG (ISIN DE0005753818) discovers and develops
targeted, small-molecule drugs for treating diseases with high unmet
medical needs in various cancer and autoimmune indications. These drugs are
intended to provide innovative treatment options that are more tolerable
and efficacious than existing therapies, and provide a better quality of
life. The Company's pipeline comprises promising products that are in
various stages of clinical development. 4SC's aim is to generate future
growth and enhance its enterprise value by entering into partnerships with
leading pharmaceutical and biotech companies. Founded in 1997, 4SC had a
headcount of 66 employees (57 FTEs) at 31 December 2014. 4SC AG has been
listed on the Prime Standard of the Frankfurt Stock Exchange since December
2005.

Cautionary statement regarding forward-looking statements
This press release contains certain forward-looking statements. Any
forward-looking statement applies only on the date of this press release.
By their nature, forward-looking statements are subject to a number of
known and unknown risks and uncertainties that may or may not occur in the
future and as a result of which the actual results and performance may
differ substantially from the expected future results or performance
expressed or implied in the forward looking statements. No warranties or
representations are made as to the accuracy, achievement or reasonableness
of such statements, estimates or projections, and 4SC AG has no obligation
to update any such information or to correct any inaccuracies herein or
omission herefrom which may become apparent.

For more information about 4SC please visit www.4sc.com or contact:

4SC AG
Jochen Orlowski, Corporate Communications & Investor Relations
jochen.orlowski(at)4sc.com, Tel.: [phone]

MC Services
Katja Arnold, Michelle Kremer
katja.arnold(at)mc-services.eu, Tel.: [phone]

The Trout Group
Chad Rubin
crubin(at)troutgroup.com, Tel.: [phone]

For more information about Menarini please visit www.menarini.com or
contact:

Jennifer Lin, Corporate Branding and Communications Asia-Pacific
JenniferCW.Lin(at)menariniapac.com, Tel: [phone]

14.04.2015 The DGAP Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de

---------------------------------------------------------------------------

Language: English
Company: 4SC AG
Am Klopferspitz 19a
82152 Martinsried
Germany
Phone: [phone]
Fax: [phone]
E-mail: [e-mail]
Internet: www.4sc.de
ISIN: DE0005753818
WKN: 575381
Listed: Regulated Market in Frankfurt (Prime Standard); Regulated
Unofficial Market in Berlin, Dusseldorf, Munich, Stuttgart

End of Announcement DGAP News-Service

---------------------------------------------------------------------------